statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) Director Yezan Munther Haddadin purchased 1,882 shares of the firm's stock in a transaction dated Thursday, March 28th. The shares were...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin Acquires 1,882 Shares

Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval...

Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) Director Yezan Munther Haddadin bought 1,882 shares of Outlook Therapeutics stock in a transaction dated Thursday, March 28th. The stock was...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin Purchases 1,882 Shares of Stock

Outlook Therapeutics files for $300M mixed securities shelf...

Outlook Therapeutics files for $300M mixed securities shelf

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Outlook Therapeutics files $300M mixed securities shelf

Outlook Therapeutics just upgraded at BTIG, here's why

Outlook Therapeutics (NASDAQ:OTLK  Free Report) had its price target increased by HC Wainwright to $30.00 in a research note released on Monday morning, Benzinga reports. HC Wainwright...

Outlook Therapeutics (NASDAQ:OTLK) Price Target Increased to $30.00 by Analysts at HC Wainwright

Outlook Therapeutics files to sell 21.43M shares of common stock for holders

This is a Bullish indicator signaling OTLK's price could rise from here. Traders may explore going long the stock or buying call options...

Outlook Therapeutics (OTLK, $8.63) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 22, 2024

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Watchers	16,287
52-Wk Low	$4.00
52-Wk High	$40.60

Volume	81,938.00
52-Wk High	$40.60
52-Wk Low	$4.00

OTLK Outlook Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals